Dear Everyone,
Re OXB
From 17th March share price was low at 400p rising to 72-75p steeply since
talk of a Covid vaccine development in conjunction with the Jenner Institute in
Oxford on April 8 thh. They technically are in a good position for this as
they developed one for Mers virus . It seems the technology would be similar
to Covid. They have started trials with volunteers who I assume will wait to
receive the virus, once they have proved to have some immunity to Covid19.
This is very speculative of course, but OXB seem to have troubles with
some litigation/legal issues with a client that the investors haven’t been
privy to. Maybe someone at the meeting can put a finger on this?
OXB also swings to a loss as licensing revenues have fallen,?why.
BUTgene and cell therapy reported improvement in bioprocessing and commercial
development.
pretax 2018 profit 5.01 mil------2016 20.31 mil none for 2019
p/e ratio 2018 61.10 n/a 2019
no dividends
peg n/a
Director Buys from Jan 2019 2020 34,
Sells 2 “ “
There does seem to be some basic insecurities with this share, but should the
vaccine be successfully developed and production fit with an enormous
demand--------------say no more!
BUT if the underlying financials are in doubt--------what then?
I leave it to you for discussion as I may not be free to join you as the honey
extraction is urgent. Daphne
Sent from Mail for Windows 10
